HWM
SABS icon

HB Wealth Management’s SAB Biotherapeutics SABS Stock Holding History

HB Wealth Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.2M Hold
307,500
– – 0.01% 669
2026
Q1 		$1.18M Hold
307,500
– – 0.01% 604
2025
Q4 		$1.15M Hold
307,500
– – 0.01% 581
2025
Q3 		$618K Buy
+307,500
New +$695K ﹤0.01% 772
2025
Q2 		– Sell
-263,200
Closed -$358K – 1276
2025
Q1 		$358K Buy
263,200
+25,800
+11% +$59.2K ﹤0.01% 891
2024
Q4 		$982K Buy
237,400
+128,800
+119% +$423K 0.01% 416
2024
Q3 		$293K Buy
+108,600
New +$301K ﹤0.01% 769

Other funds holding SABS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

HB Wealth Management's SABS Position: Q2 2026 in Review

HB Wealth Management held its SAB Biotherapeutics (SABS) position steady in Q2 2026 at 307,500 shares worth $1.2M. The position accounts for 0.01% of the portfolio, ranked #669.

HB Wealth Management first reported a position in SABS in Q3 2024 and has held it in 7 quarters since. 49 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • HB Wealth Management held 307,500 shares of SAB Biotherapeutics worth $1.2M as of Q2 2026.
  • HB Wealth Management left its SAB Biotherapeutics share count unchanged in Q2 2026.
  • SAB Biotherapeutics made up 0.01% of HB Wealth Management's portfolio in Q2 2026, its #669 holding.
  • HB Wealth Management first reported a position in SAB Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • 49 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.